L3VLUP
ProSign in

CTMX in the 13F filings

Cytomx Therapeutics Inc · CUSIP 23284F105

Sector · Pharmaceuticals and biotechnologyTheme · Healthcare: biopharma and medtech· L3VLUP-definedTheme · Pharmaceutical preparations
Quarter
Q4 2025Q3 2025Q1 2024Q2 2023Q4 2022Q3 2022Q1 2022Q4 2021Q3 2021Q2 2021Q1 2021Q4 2020
Quarter end
30 Sep 2021
the date the book describes
Filed
15 Nov 2021
latest of these filings; the earliest 15 Nov 2021
Managers listing it
2
at least, of 95 tracked, among listed positions
Comparable managers
93
filed both Q2 2021 and Q3 2021; 1 listed it in both
Shares listed
6,408,833
combined, among listed positions
Reported value
$33m
combined, at the quarter end

Managers listing CTMX in Q3 2021

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q2 2021, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

2 of 2 holders

ActionFiling
Point72 Asset Management LP6,303,025$32m0.14%Trimmed-90,87515 Nov 2021 (the filing on sec.gov)
PDT Partners LLC105,808$539kunder 0.1%Addedn.a.15 Nov 2021 (the filing on sec.gov)

Largest increases and reductions, by shares

Q2 2021 to Q3 2021, among managers that listed it in both quarters or opened it.

Increases

No increase among listed positions.

Reductions

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (0)

No new position among listed positions.

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
2 in Q4 2021 to 1 in Q4 2025

Tracked managers listing it, at least.

01234201820192020202120222024
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
CTMX by quarter
QuarterHoldersReported valueBuyersSellers
Q1 20183$12mn.a.n.a.
Q2 20181$494kn.a.n.a.
Q3 20182$27mn.a.n.a.
Q4 20182$24mn.a.n.a.
Q1 20192$8.1mn.a.n.a.
Q2 20191$1.4mn.a.n.a.
Q3 20192$1.4mn.a.n.a.
Q4 20193$7.6mn.a.n.a.
Q1 20203$1.5mn.a.n.a.
Q2 20204$11mn.a.n.a.
Q3 20203$5.1mn.a.n.a.
Q4 20202$1.0mn.a.n.a.
Q1 20212$56mn.a.n.a.
Q2 20212$47mn.a.n.a.
Q3 20212$33mn.a.n.a.
Q4 20212$28mn.a.n.a.
Q1 20221$12mn.a.n.a.
Q3 20221$3.8mn.a.n.a.
Q4 20221$4.2mn.a.n.a.
Q2 20231$4.6mn.a.n.a.
Q1 20241$5.9m10
Q3 20251$7.5m10
Q4 20251$10.0m115

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

CTMX and LLY →CTMX and JNJ →CTMX and VRTX →Choose a stock to compare with CTMX →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own CTMX, latest filings →Back to the 13F Explorer →